Citations

Clear

65 citation(s) found for "Tepper, SJ".

Abstract 2159: A pretreatment blood-based proteomic biomarker for enhanced decision-making in non-small cell lung cancer
Harel, Michal , Christopoulos, Petros , Sela, Itamar , Dahan, Nili, Koch, Ina , Moskovitz, Mor, Levy‐Barda, Adva , Lotem, Michal, Katzenelson, Rivka, Abu-Amna, Mahmoud, Gottfried, Maya, Wolf, Ido , Tepper, Ella, Lou, Yanyan , Dicker, Adam P. , Gandara, David, Dicker, Adam P , Lahav, Coren , Reinmuth, Niels , Zer Kuch, Alona , Nechushtan, Hovav , Agbarya, Abed , Leibowitz‐Amit, Raya , Carbone, David Paul

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 2159-2159

10.1158/1538-7445.am2023-2159 Get It

Abstract Introduction: Treatment modality selection for metastatic NSCLC patients (immunotherapy alone vs. combination of immunotherapy with chemotherapy) relies mainly on determining the programmed cell death 1 (PD-L1) expression levels in the tumor. However, available assays are only moderately predictive. Here we set to develop PROphet®, a plasma proteomics-based predictive model for informing treatment decisions for NSCLC patients receiving immune checkpoint inhibitor (ICI)-based therapy. Methods: Pre-ICI plasma samples were collected in 12 centers in a clinical trial (NCT04056247) from 367 advanced-stage NSCLC patients. Clinical benefit (CB) was assessed at 12 months based on the occurrence of progression-free survival (PFS) until this time point. Deep proteomic profiling of the plasma samples was performed using aptamer-based technology. A novel machine learning model was developed to determine the CB probability for each patient, and the performance was successfully evaluated on an independent validation set, followed by training and prediction over the entire cohort using cross-validation. The resulting PROphet® score (positive or negative) was determined by setting the median CB rate probability as a threshold. The patients were divided into four subgroups based on their PD-L1 expression level combined with their PROphet® score prediction, and the overall survival (OS) was examined for each subgroup. Results: The PROphet® computational model was evaluated in a blinded manner on a subset of 85 patients and displayed strong predictive capability with area under the curve (AUC) of the receiver operating characteristics (ROC) plot of 0.78 (p-value = 5.00e-05), outperforming a PD-L1-based predictive model (AUC = 0.62; p-value 2.76e-01). When combining PROphet® score with PD-L1 expression levels, four different outcome patterns were identified: (i) Patients with PD-L1 ≥50% and PROphet® negative score, who displayed significantly longer OS when treated with ICI-chemotherapy combination therapy compared to ICI monotherapy and may consider combination therapy. (ii) Patients with PD-L1 ≥50% and PROphet® positive score, who benefit similarly from either treatment modalities, and may consider monotherapy to avoid the potential toxicity of the combination therapy. (iii) Patients with PD-L1<50% and PROphet® negative score, who do not benefit from either treatment modalities and may consider chemotherapy alone or treatment beyond standard of care. (iv) Patients with PD-L1<50% and PROphet® positive score who benefit from combination therapy. Conclusions: Altogether, the PROphet® model, when combined with PD-L1 test, stratifies the patients into four subgroups, providing additional resolution to the PD-L1 biomarker currently used to guide treatment selection. Furthermore, the model accurately predicts CB at 12 months based on proteomic analysis of a pre-treatment plasma sample. Citation Format: Michal Harel, Petros Christopoulos, Coren Lahav, Itamar Sela, Nili Dahan, Niels Reinmuth, Ina Koch, Alona Zer, Mor Moskovitz, Adva Levy-Barda, Michal Lotem, Hovav Nechushtan, Rivka Katzenelson, Abed Agbarya, Mahmoud Abu-Amna, Maya Gottfried, Ido Wolf, Ella Tepper, Yanyan Lou, Raya Leibowitz, Adam P. Dicker, David Gandara, David P. Carbone. A pretreatment blood-based proteomic biomarker for enhanced decision-making in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2159.
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache
Schoenen, Jean , Snoer, Agneta, Brandt, Roemer B. , Fronczek, Rolf , Wei, Diana Y. , Chung, Chin‐Sang , Diener, Hans‐Christoph , Goadsby, Peter J. , Matharu, Manjit , McGinley, James S., Tepper, Stewart J. , Brandt, Roemer W, Tassorelli, Cristina , Leroux, Élizabeth , Christensen, Marie Deen, Goadsby, Peter J , Matharu, Manjit Singh , May, Arne , Diener, Hans-Christoph , Schoenen, Jean , Dodick, David W. , Fontaine, Denys , May, Arne , Jensen, Rigmor , Ferrari, Michel D. , Terwindt, Gisela M. , Ashina, Messoud , Lipton, Richard B. , Pozo‐Rosich, Patricia , Wang, Shuu‐Jiun , Martini, Daniela, Hoek, Thomas C. van den

Mayo Clinic

Cephalalgia | August 18, 2022 | Volume: 42 | Issue: 14 | Pages: 1450-1466

10.1177/03331024221120266 | PMID 36268950 Get It

In 1995, a committee of the International Headache Society developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Cluster Headache. These have not been revised. With the emergence of new medications, neuromodulation devices and trial designs, an updated version of the International Headache Society Guidelines for Controlled Clinical Trials in Cluster Headache is warranted. Given the scarcity of evidence-based data for cluster headache therapies, the update is largely consensus-based, but takes into account lessons learned from recent trials and demands by patients. It is intended to apply to both drug and neuromodulation treatments, with specific proposals for the latter when needed. The primary objective is to propose a template for designing high quality, state-of-the-art, controlled clinical trials of acute and preventive treatments in episodic and chronic cluster headache. The recommendations should not be regarded as dogma and alternative solutions to particular methodological problems should be explored in the future and scientifically validated.
An IL-9–pulmonary macrophage axis defines the allergic lung inflammatory environment
Fu, Yongyao , Wang, Jocelyn , Zhou, Baohua , Pajulas, Abigail , Gao, Hongyu , Ramdas, Baskar , Koh, Byunghee , Ulrich, Benjamin J. , Yang, Shuangshuang , Kapur, Reuben , Licona-Limón, Paula , Takatsuka, Shogo , Kitamura, Daisuke , Kaplan, Mark H. , Renauld, Jean-Christophe , Paczesny, Sophie , Liu, Yunlong , Tighe, Robert M , Licona-Limón, Paula , Flavell, Richard A , Takatsuka, Shogo , Tepper, Robert S , Sun, Jie , Kaplan, Mark H , Tighe, Robert M. , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | February 18, 2022 | Volume: 7 | Issue: 68 | Pages: No page available

10.1126/sciimmunol.abi9768 | PMID 35179949 Get It

Despite IL-9 functioning as a pleiotropic cytokine in mucosal environments, the IL-9–responsive cell repertoire is still not well defined. Here, we found that IL-9 mediates proallergic activities in the lungs by targeting lung macrophages. IL-9 inhibits alveolar macrophage expansion and promotes recruitment of monocytes that develop into CD11c + and CD11c − interstitial macrophage populations. Interstitial macrophages were required for IL-9–dependent allergic responses. Mechanistically, IL-9 affected the function of lung macrophages by inducing Arg1 activity. Compared with Arg1-deficient lung macrophages, Arg1-expressing macrophages expressed greater amounts of CCL5. Adoptive transfer of Arg1 + lung macrophages but not Arg1 − lung macrophages promoted allergic inflammation that Il9r −/− mice were protected against. In parallel, the elevated expression of IL-9, IL-9R, Arg1, and CCL5 was correlated with disease in patients with asthma. Thus, our study uncovers an IL-9/macrophage/Arg1 axis as a potential therapeutic target for allergic airway inflammation.
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura
Goadsby, Peter J. , Tepper, Stewart J. , Xue, Fei , Brennan, F. James, Lima, Gabriel Paiva da Silva , Goadsby, Peter J , Lima, Gabriel Paiva da Silva , Ashina, Messoud , Dodick, David W. , Zhang, Feng , Brennan, Francis

Mayo Clinic

JAMA Neurology | December 20, 2021 | Volume: 79 | Issue: 2 | Pages: 159

10.1001/jamaneurol.2021.4678 | PMID 34928306 Get It

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
Marmura, Michael J. , Diener, Hans‐Christoph, Cowan, Robert P. , Tepper, Stewart J. , Diamond, Merle L., Starling, Amaal J. , Hirman, Joe, Mehta, Lahar, Brevig, Thomas, Cady, Roger , Marmura, Michael J , Cowan, Robert P , Diener, Hans‐Christoph

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 21, 2021 | Volume: 61 | Issue: 9 | Pages: 1421-1431

10.1111/head.14206 | PMID 34551130 Get It

Abstract Objective This post hoc analysis in patients medically diagnosed with chronic migraine (CM) and medication‐overuse headache (MOH) evaluated reductions in the use of acute headache medication (AHM) and sustained changes in the diagnostic status of CM and MOH following eptinezumab treatment in the PROMISE‐2 study. Background Eptinezumab, a monoclonal antibody that inhibits calcitonin gene‐related peptide, is approved in the United States for the preventive treatment of migraine. A previous analysis showed that eptinezumab reduced monthly migraine days and was well tolerated in the subgroup of PROMISE‐2 patients diagnosed with both CM and MOH. Methods The phase 3, double‐blind, placebo‐controlled PROMISE‐2 study (NCT02974153) randomized adults with CM to eptinezumab 100 mg, 300 mg, or placebo (administered intravenously every 12 weeks for up to two doses). MOH was prospectively diagnosed at screening by trained physicians based on 3 months of medication history and International Classification of Headache Disorders‐3β criteria. This post hoc analysis evaluated changes in total and class‐specific days of AHM usage, the percentage of patients using AHM at or above MOH diagnostic thresholds, and the percentage of patients experiencing monthly headache and migraine day frequency below diagnostic thresholds for MOH and/or CM. Results In PROMISE‐2, 431/1072 (40.2%) patients with CM were diagnosed with MOH (eptinezumab 100 mg, n = 139; 300 mg, n = 147; placebo, n = 145) and were included in this analysis. Total monthly AHM use decreased from 20.6 days/month at baseline to 10.6 days/month over 24 weeks of treatment (49% decrease) with eptinezumab 100 mg, from 20.7 to 10.5 days/month (49% decrease) with eptinezumab 300 mg, and from 19.8 to 14.0 days/month (29% decrease) with placebo. Numerically greater decreases from baseline with eptinezumab were also observed for individual drug classes. In each study month, the percentages of patients who were below MOH thresholds were numerically higher for both eptinezumab doses compared with placebo, as were the percentages of patients experiencing headache and migraine frequency below CM thresholds. Of patients with available data across the entire treatment period, 29.0% (58/200) of patients treated with eptinezumab stopped meeting and remained below diagnostic thresholds for both CM and MOH during Weeks 1–24, as well as 6.3% (6/96) of patients who received placebo. Conclusions Across 24 weeks of treatment, eptinezumab reduced AHM use in patients diagnosed with CM and MOH. More than one‐fourth (29%) of patients treated with eptinezumab did not meet the diagnostic thresholds for either CM or MOH for the entire treatment period.
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
Dodick, David W. , Tepper, Stewart J. , Pannacciulli, Nicola, Navetta, Marco S., Loop, Brett, Zhang, Feng , Khodavirdi, Ani C., Mann, Allison, Abdrabboh, Ahmad, Kalim, Jawed, Dodick, David W , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 30, 2021 | Volume: 61 | Issue: 9 | Pages: 1411-1420

10.1111/head.14208 | PMID 34591982 Get It

Abstract Objective To assess the risk of hypertension in patients with migraine who received erenumab in clinical trials and in the postmarketing setting. Background Erenumab is a monoclonal antibody for migraine prevention that targets the calcitonin gene‐related peptide (CGRP) receptor. Hypertension is a theoretical risk for inhibitors of the CGRP pathway. Although no evidence of an association between erenumab treatment and hypertension was observed during the clinical development program, adverse events (AEs) of hypertension have been identified in the postmarketing setting. Methods Safety data from four phase 2 and phase 3 clinical trials were used to perform a pooled analysis of hypertension AEs in patients with migraine receiving erenumab. Postmarketing AEs of hypertension were identified from the Amgen Global Safety database from May 17, 2018, through January 31, 2020. Results In the pooled analysis of clinical trials, hypertension AEs (placebo, 9/1043 [0.9%]; erenumab 70 mg, 7/893 [0.8%]; erenumab 140 mg, 1/507 [0.2%]) and percentage of patients initiating medication to treat hypertension (12/1043 [1.2%], 7/893 [0.8%], 1/507 [0.2%], respectively) were similar across treatment groups. A total of 362 AEs of hypertension were identified from the postmarketing setting, 26.2% (95/362) of which were serious, >245,000 patient‐years of exposure. The exposure‐adjusted incidence of hypertension was 0.144 per 100 patient‐years. Conclusions Clinical trials did not demonstrate an increased risk of hypertension with erenumab compared with placebo, and AE rates of hypertension reported with erenumab in the postmarketing setting were generally low. Additional data are needed to fully characterize the extent to which hypertension is a risk associated with erenumab.
Timing and durability of response to erenumab in patients with chronic migraine
Tepper, Stewart J. , Lucas, Sylvia , Scanlon, James, Klatt, Jan , Chou, Denise E. , Wang, Andrea , Ashina, Messoud , Ashina, Messoud , Schwedt, Todd J. , Ailani, Jessica , Lima, Gabriel Paiva da Silva

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 7, 2021 | Volume: 61 | Issue: 8 | Pages: 1255-1263

10.1111/head.14193 | PMID 34363708 Get It

Abstract Background Erenumab is a human anti‐calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response. Methods This is a post hoc analysis of a 12‐week, randomized, double‐blind, placebo‐controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%). Results Among the erenumab 140 mg group ( n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group ( n = 188). Conclusion A majority of erenumab‐treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.
Venlafaxine prescription claims among insured women of reproductive age and pregnant women, 2011–2016
Summers, April D. , Anderson, Kayla N. , Ailes, Elizabeth C. , Grosse, Scott D. , Tepper, Naomi K. , Reefhuis, Jennita , Bobo, William V. , Grosse, Scott D

Mayo Clinic

Birth Defects Research | April 16, 2021 | Volume: 113 | Issue: 14 | Pages: 1052-1056

10.1002/bdr2.1897 | PMID 33860984 Get It

AbstractBackgroundSome studies have reported associations between prenatal use of venlafaxine, a serotonin‐norepinephrine reuptake inhibitor used for depressive and anxiety disorders, and some birth defects. We described the prevalence of venlafaxine prescription claims among privately insured women of reproductive age and pregnant women.MethodsVenlafaxine prescription claims were examined using the IBM MarketScan Commercial Databases. We included women of reproductive age (15–44 years) who had ≤45 days of lapsed enrollment during the calendar year of interest (2011–2016) in a non‐capitated healthcare plan sponsored by a large, self‐insured employer with prescription drug coverage and no mental health service carve‐out. Annual cohorts of pregnant women were identified among eligible women of reproductive age via pregnancy diagnosis and procedure codes. Venlafaxine prescriptions were identified via National Drug Codes in outpatient pharmacy claims and we estimated the annual proportion of women with venlafaxine claims by pregnancy trimester (pregnant women only), age, and Census division.ResultsEach year during 2011–2016, approximately 1.2% of eligible reproductive‐aged and 0.3% of eligible pregnant women filled a venlafaxine prescription. Among pregnant women, the proportion with venlafaxine claims was highest during the first trimester and decreased during the second and third trimesters. Small temporal increases in venlafaxine claims were observed for reproductive‐aged and pregnant women, with the largest among women aged 15–19 years.ConclusionsVenlafaxine prescription claims were low among women of reproductive age and pregnant women during 2011–2016, with some increasing use over time among women aged 15–19 years.
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study
Kawata, Ariane K., Shah, Neel , Poon, Jiat Ling , Shaffer, Shannon, Sapra, Sandhya, Wilcox, Teresa K. , Shah, Shweta, Tepper, Stewart J. , Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 20, 2021 | Volume: 61 | Issue: 3 | Pages: 438-454

10.1111/head.14053 | PMID 33594686 Get It

Abstract Background Calcitonin gene‐related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the patterns which preceded their introduction. Objective To characterize the burden, unmet need, and treatment patterns in patients with migraine initiating preventive migraine medications before the introduction of CGRP inhibitors in the US. Methods Between March 2016 and October 2017, we enrolled episodic (EM) and chronic migraine (CM) patients initiating or changing preventive treatment at primary care or neurology clinic visits in the US, in a real‐world observational study using a prospective cohort design. At baseline and monthly thereafter for 6 months, we collected data from study sites and patients on migraine frequency, treatment modifications, migraine impact on functioning, and work productivity for a descriptive analysis of migraine patient experience and treatment patterns. Results From the sample of 234 completers, 118 had EM (50.4%) and 116 had CM (49.6%). Mean age at enrollment was 41 years (SD = 12) and mean age at first migraine diagnosis was 22 years (SD = 11). Most participants were females ( n = 204/234; 87.2%) and white ( n = 178/234; 76.1%). The majority ( n = 164/234; 70.1%) had not used preventive migraine treatment in the 5 years prior to enrollment (treatment naïve). At baseline, mean monthly migraine days were 9.6 days (SD = 5.0) for the preventive treatment naïve group and 12.4 days (SD = 7.0) for treatment experienced patients. The majority had severe Migraine Disability Assessment (Grade IV, total score ≥21), including 67.1% ( n = 110/164) of the preventive treatment naïve and 77.1% ( n = 54/70) of the preventive treatment experienced patients. Headache Impact Test total scores indicating severe impairment (score >59) occurred in 88.4% ( n = 145/164) of the treatment naïve and 88.6% ( n = 62/70) of treatment experienced patients. Mean work productivity loss as measured by the Work Productivity and Activity Impairment questionnaire in the subsample of employed patients was 53.3% loss. The most used acute medications at baseline were nonsteroidal anti‐inflammatory agents ( n = 124/234; 53.0%), acetaminophen‐based products ( n = 112/234; 47.9%), and triptans ( n = 105/234; 44.9%). The most commonly initiated preventive treatments were topiramate ( n = 100/234; 42.7%), tricyclic antidepressants ( n = 39/234; 16.7%), beta‐blockers ( n = 26/234; 11.1%), and onabotulinumtoxinA ( n = 24/234; 10.3%). Over the 6‐month follow‐up period, almost half of patients ( n = 116/234, 49.6%) modified their preventive treatment and discontinued treatment ( n = 88/312 total modifications; 28.2%) or modified their pattern of use by increasing, decreasing, or skipping doses ( n = 224/312 total modifications; 71.8%), often without seeking medical advice. Avoiding side effects was the main reason reported among patients who discontinued ( n = 52/88; 59.1%), decreased frequency or dose ( n = 37/89; 41.6%), and skipped doses ( n = 29/86; 33.7%). Perceived lack of efficacy was another frequent reason reported among those who discontinued ( n = 20/88; 22.7%), decreased frequency or dose ( n = 15/89; 16.9%), and skipped doses ( n = 18/86; 20.9%). Despite initiation of preventive treatment and improvements observed in number of headache and migraine days, migraine patients continued to experience substantial disability, headache impact, and reduced productivity throughout the 6‐month follow‐up period. Conclusions Prior to 2018, the burden of migraine was high for patients initiating preventive treatments. Despite having more than 9 days of migraine per month on average, the majority (70.1%) of patients initiating prevention had been treatment naïve, indicating underuse of preventive treatments. The preventive treatments used in this study were poorly tolerated and were reported by patients to lack efficacy, resulting in suboptimal adherence. The high discontinuation rates suggest that the preventive medications being offered during the period of the study did not meet the treatment needs of patients. In addition, the decisions by about half of patients to alter their prescribed treatment plan without consulting their provider can pose substantial health risks. These findings pertain to the broad set of preventive treatments initiated in this study and do not support inferences about individual preventive treatments, due to limitations in sample size. These findings suggest the need for more effective and better tolerated preventive treatment options.
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2
Marmura, Michael J. , Tepper, Stewart J. , Cowan, Robert P. , Starling, Amaal J. , Diamond, Merle L., Hirman, Joe, Mehta, Lahar, Brevig, Thomas, Sperling, Bjørn, Cady, Roger , Marmura, Michael J , Cowan, Robert P , Diener, Hans‐Christoph

Mayo Clinic

Headache: The Journal of Head and Face Pain | December 14, 2020 | Volume: 61 | Issue: 1 | Pages: 125-136

10.1111/head.14036 | PMID 33314079 Get It

Abstract Objective To evaluate the efficacy, tolerability, and safety of eptinezumab 100 and 300 mg compared with placebo in patients with the dual diagnosis of chronic migraine (CM) and medication‐overuse headache (MOH). Background Eptinezumab, a humanized monoclonal antibody targeting calcitonin gene‐related peptide, may be effective for treating patients with a dual diagnosis of CM and MOH. Methods PROMISE‐2 (NCT02974153) was a double‐blind, randomized, placebo‐controlled, phase 3 study that comprised a screening visit, a 28‐day pretreatment period, and a 32‐week study duration. Patients in this exploratory analysis of a prespecified subgroup had confirmed diagnoses of both CM and MOH at screening. Patients were randomly assigned to receive intravenous eptinezumab 100, 300 mg, or placebo every 12 weeks. Efficacy outcomes included mean changes from baseline in monthly migraine days (MMDs) during weeks 1–12, migraine responder rates at week 12, and percentages of patients below International Classification of Headache Disorders thresholds for CM and MOH over weeks 1–24. Results There were 431 patients who were diagnosed with CM and MOH as specified in the protocol and received eptinezumab 100 mg ( n = 139), 300 mg ( n = 147), or placebo ( n = 145). During the baseline period, these patients experienced an average of 16.7 migraine days across treatment arms. Over weeks 1–12, eptinezumab‐treated patients experienced greater reductions from baseline in MMDs than placebo patients (100 mg, change from baseline = −8.4, difference from placebo [95% confidence interval (CI)] = −3.0 [−4.56, −1.52], p < 0.0001 vs. placebo; 300 mg, change from baseline = −8.6, difference from placebo [95% CI] = −3.2 [−4.66, −1.78], p < 0.0001 vs. placebo; placebo, −5.4). Compared with placebo, more eptinezumab‐treated patients were ≥50% migraine responders (100 mg, 84/139 [60.4%]; 300 mg, 91/147 [61.9%]; placebo, 50/145 [34.5%]) or ≥75% responders (100 mg, 38/139 [27.3%]; 300 mg, 44/147 [29.9%]; placebo, 21/145 [14.5%]) over weeks 1–12. Therapeutic benefits with eptinezumab were observed from day 1 after dosing, and improvements were sustained with an additional dose. For the full 24‐week treatment period, 71/139 (51.1%), 80/147 (54.4%), and 47/145 (32.4%) of 100, 300 mg, and placebo‐treated patients, respectively, were below CM thresholds, and of the patients who provided sufficient acute medication data, 47/93 (50.5%), 53/107 (49.5%), and 26/96 (27.1%), respectively, were below medication‐overuse thresholds. Conclusions In patients diagnosed with both CM and MOH, eptinezumab treatment resulted in greater reductions in MMDs, higher responder rates, and fewer patients meeting CM and MOH criteria, thus demonstrating the efficacy and clinical utility of eptinezumab in this patient population.